125 related articles for article (PubMed ID: 2572262)
1. The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog.
Hadfield SE; Slee SJ; Snow HM
Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):78S-81S. PubMed ID: 2572262
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
[TBL] [Abstract][Full Text] [Related]
3. Haemodynamics in postural hypotension--effects of the beta-adrenoceptor partial agonist xamoterol, and pindolol.
Mehlsen J; Trap-Jensen J
Eur Heart J; 1990 Apr; 11 Suppl A():56-8. PubMed ID: 1971593
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of xamoterol, prenalterol and salbutamol as assessed by their effects in the presence and absence of ICI 118 551.
McCaffrey PM; Riddell JG; Shanks RG
Eur Heart J; 1990 Apr; 11 Suppl A():54-5. PubMed ID: 1971592
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the properties of prenalterol and corwin at beta 1- and beta 2-adrenoreceptors in vitro.
Gurden JM; Apperley GH; Drew GM
J Auton Pharmacol; 1989 Apr; 9(2):79-91. PubMed ID: 2565903
[TBL] [Abstract][Full Text] [Related]
6. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551.
McCaffrey PM; Riddell JG; Shanks RG
J Cardiovasc Pharmacol; 1988 May; 11(5):543-51. PubMed ID: 2455840
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological analysis of the cardiac actions of xamoterol, a beta adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: evidence for involvement of adenylate cyclase system in its cardiac stimulant actions.
Hattori Y; Sakuma I; Nakao Y; Kanno M
J Pharmacol Exp Ther; 1987 Sep; 242(3):1077-85. PubMed ID: 2888870
[TBL] [Abstract][Full Text] [Related]
8. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.
McCaffrey PM; Riddell JG; Shanks RG
Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634
[TBL] [Abstract][Full Text] [Related]
9. Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function.
Rousseau MF; Pouleur H; Debaisieux JC; Van Eyll C; Charlier AA
Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):84S-85S. PubMed ID: 2572264
[TBL] [Abstract][Full Text] [Related]
10. Studies of the agonist and antagonist activity of cicloprolol in man.
McCaffrey PM; Burke M; Riddell JG; Shanks RG
Eur J Clin Pharmacol; 1988; 34(6):569-75. PubMed ID: 3169110
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of beta-adrenoceptor partial agonists on isolated rat atrium.
Vigholt-Sørensen E; Påby L; Halliday SE; Snow HM
Pharmacol Toxicol; 1991 Nov; 69(5):351-4. PubMed ID: 1687080
[TBL] [Abstract][Full Text] [Related]
12. Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects.
Tomlinson B; Cruickshank JM; Hayes Y; Renondin JC; Lui JB; Graham BR; Jones A; Lewis AD; Prichard BN
Br J Clin Pharmacol; 1990 Nov; 30(5):665-72. PubMed ID: 1980200
[TBL] [Abstract][Full Text] [Related]
13. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.
Nuttall A; Snow HM
Br J Pharmacol; 1982 Oct; 77(2):381-8. PubMed ID: 6128041
[TBL] [Abstract][Full Text] [Related]
14. Heart-rate variability effects of beta-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods.
Silke B; Hanratty CG; Riddell JG
J Cardiovasc Pharmacol; 1999 Jun; 33(6):859-67. PubMed ID: 10367588
[TBL] [Abstract][Full Text] [Related]
15. The in vitro pharmacology of xamoterol (ICI 118,587).
Malta E; Mian MA; Raper C
Br J Pharmacol; 1985 May; 85(1):179-87. PubMed ID: 2862938
[TBL] [Abstract][Full Text] [Related]
16. Cetamolol: cardiovascular effects of a new cardioselective beta-adrenoceptor blocker possessing partial agonistic activity and lacking membrane-stabilizing activity.
Beaulieu G; Grimes D; Muirhead C; Oshiro G
Can J Physiol Pharmacol; 1984 Jun; 62(6):610-6. PubMed ID: 6146394
[TBL] [Abstract][Full Text] [Related]
17. The electrophysiological effects of intravenous xamoterol in man.
Bowes RJ; Gautam PC; Graham DR; Harley A
Eur J Clin Pharmacol; 1986; 29(6):731-4. PubMed ID: 2872057
[TBL] [Abstract][Full Text] [Related]
18. Immediate central and regional haemodynamic effects of a new beta 1-adrenergic stimulating drug, xamoterol (Corwin) in healthy volunteers.
Tangø M; Carlsen JE; Trap-Jensen J
Eur J Clin Pharmacol; 1985; 29(2):155-8. PubMed ID: 2866963
[TBL] [Abstract][Full Text] [Related]
19. Independent regulation of beta 1- and beta 2-adrenoceptors.
Beer M; Hacker S; Poat J; Stahl SM
Br J Pharmacol; 1987 Dec; 92(4):827-34. PubMed ID: 2892556
[TBL] [Abstract][Full Text] [Related]
20. The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.
Snow HM
Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):3S-13S. PubMed ID: 2572252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
